Decera Clinical Education Oncology Podcast
Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.
TROP2-Directed ADCs in NSCLC: Current Evidence, Emerging Therapies, and Future Treatment Strategies
In this podcast episode, Christine M. Bestvina, MD, and Joshua E. Reuss, MD, discuss the current and emerging role of TROP2-directed ADCs in NSCLC, including:
Current clinical use of Dato-DXd in previously treated EGFR-mutated NSCLC, including evidence from TROPION-Lung01 and TROPION-Lung05 and considerations for treatment sequencingEmerging efficacy data for investigational TROP2 ADCs, including sacituzumab tirumotecan, and the potential role of these agents in earlier lines of therapyOngoing clinical trials evaluating TROP2 ADCs alone and in combination with immunotherapy, chemotherapy, or EGFR-targeted therapies, including TROPION-Lung07, TROPION-Lung08, TROPION-Lung14, TROPION-Lung15, and AVANZARBiomarker-guided patient selection, including the potential of the TROP2...Experts Discuss Key Topics in Treatment for Newly Diagnosed Multiple Myeloma
In this podcast episode, Jesus G. Berdeja, MD, and Ajai Chari, MD, discuss evolving therapy in newly diagnosed multiple myeloma, including:
Selecting quadruplet therapyOptimal use of bortezomibThe role of autologous stem cell transplantation in the quadruplet eraUse of MRD status to inform treatment decisionsMaintenance strategiesPresenters:
Jesus G. Berdeja, MD
Director of Myeloma Research
Greco-Hainsworth Centers for Research
Partner
Tennessee Oncology
Nashville, Tennessee
Ajai Chari, MD
Professor of Clinical Medicine
Director of Multiple Myeloma Program
UCSF Helen Diller Family Comprehensive Cancer Center
University of Ca...
PARP Inhibitors in Metastatic Prostate Cancer: Biomarker Testing, Treatment Strategies, and Toxicity Management
In this podcast episode, Neeraj Agarwal, MD, FASCO, and Emmanuel S. Antonarakis, MD, discuss the evolving role of PARP inhibitors in metastatic prostate cancer, emphasizing early molecular testing to identify appropriate patients for PARP-directed therapy and proactive adverse event management to support treatment continuation, including:
HRR alterations and the mechanism of action of PARP inhibitorsGermline and somatic genomic testing and practical considerations for tissue and ctDNA testingPARP inhibitor monotherapy and combination strategies, including data from AMPLITUDE and TALAPRO-3Treatment selection across metastatic prostate cancer settings based on HRR alterationsPARP inhibitor toxicity management, with emphasis on anemia, gastrointestinal effects...Experts Discuss Sequencing of Therapies for Relapsed/Refractory Multiple Myeloma
Listen to Jesus G. Berdeja, MD, and Ajai Chari, MD, as they discuss sequencing of antibody–drug conjugates (ADCs), bispecific antibodies, CAR T-cell therapy, and other novel treatment modalities for patients with relapsed/refractory multiple myeloma.
Presenters:
Jesus G. Berdeja, MD
Director of Myeloma Research
Greco-Hainsworth Centers for Research
Partner
Tennessee Oncology
Nashville, Tennessee
Ajai Chari, MD
Professor of Clinical Medicine
Director of Multiple Myeloma Program
UCSF Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco (UCSF) Medical Center
San Francisco, California
ASCO 2026 Updates in Metastatic Breast Cancer
In this podcast episode, Hope S. Rugo, MD, FASCO, and Nerea Lopetegui-Lia, MD, discuss practice-informing data presented at ASCO 2026 for patients with metastatic breast cancer, including:
Findings from SERENA-6 on ctDNA-guided treatment switching for emergent ESR1 mutations before radiographic progression, including updated PFS2 and downstream treatment outcomesEmerging precision strategies in HR-positive/HER2-negative advanced breast cancer from ELEVATE and PIKALO-1, including elacestrant plus capivasertib and mutant-selective PI3Kα inhibition with tersolisibFirst-line TROP2-directed ADC data from ASCENT-04, ASCENT-03, and TROPION-Breast02, with discussion of PFS2, subsequent therapy, immunotherapy eligibility, and treatment sequencing
Presenters:
Hope S. Rug...
Evolving Role of B7-H3–Directed ADCs in the Extensive-Stage Small-Cell Lung Cancer Treatment Landscape
In this podcast episode, Charles Rudin, MD, PhD, and Mark A. Socinski, MD, discuss current gaps and clinical needs for patients with relapsed ES-SCLC, and the evolving role of B7-H3–directed antibody–drug conjugates in the management of patients with ES-SCLC, including:
Clinical needs for relapsed ES-SCLCScientific rationale for targeting B7-H3 and other tumor-associated antigens in SCLCADCs, T-cell engagers, chemotherapy-based approaches, maintenance strategies, and ongoing clinical trials for ES-SCLCRecent efficacy and safety data for B7-H3–directed ADCs in ES-SCLC, including I-DXdPersonalization of care of patients with SCLC, including patient-specific factors influencing treatmentCase discussion of a patien...Targeting CDH6 in Platinum-Resistant Ovarian Cancer: Emerging ADCs, Biomarkers, and Sequencing
In this podcast episode, BJ Rimel, MD, and Elizabeth Lee, MD, discuss the scientific rationale for targeting CDH6 in ovarian cancer and the emerging role of CDH6-directed antibody–drug conjugates (ADCs) in platinum-resistant disease, including:
CDH6 biology, expression patterns, and its potential as a therapeutic target in ovarian cancerEarly-phase efficacy data with investigational CDH6-directed ADCs, including raludotatug deruxtecan (R-DXd) and CUSP06, and an ongoing phase III trial of R-DXdSafety considerations with CDH6-directed ADCs, including cytopenias, gastrointestinal toxicities, fatigue, and interstitial lung disease/pneumonitisConsiderations for sequencing ADCs, including the potential impact of target expression, payload class, an...ASCO 2026 Updates in Early Hormone Receptor–Positive Breast Cancer
In this podcast episode, Hope S. Rugo, MD, FASCO, and Nerea Lopetegui-Lia, MD, discuss practice-informing data presented at ASCO 2026 for patients with early-stage hormone receptor (HR)–positive/HER2-negative breast cancer, including:
Findings from the OPTIMA trial evaluating Prosigna gene expression testing to guide adjuvant chemotherapy decisions in patients with high-risk HR-positive/HER2-negative early breast cancerThe importance of ovarian function suppression plus endocrine therapy when considering chemotherapy-sparing strategies in premenopausal patientsResults from the NATALEE PAM50 biomarker analysis, showing ribociclib benefit across intrinsic subtypes with no significant treatment-by-subtype interactionPresenters:
Hope S. Rugo, MD, FASCO
CELMoDs on the Horizon: A New Chapter in Lymphoma Care
Treatment options for patients with lymphoma are rapidly evolving. In this podcast episode, Alex F. Herrera, MD, and Marc Hoffmann, MD, discuss cereblon E3 ligase modulators (CELMoDs) as potential treatment options for patients with aggressive diffuse large B-cell lymphoma and follicular lymphoma, with a focus on golcadomide, an investigational, oral, first-in-class CELMoD therapy. Topic areas covered include:
Biologic and clinical rationale for the use of CELMoD therapy in lymphoma patients Emerging clinical trial data on golcadomide alone and in combination with other regimens Real-world expectations for incorporating CELMoD-based therapies into community lymphoma care settings such as efficacy, patient se...Experts Discuss Health Disparities and Equitable Care Strategies in Multiple Myeloma
In this podcast episode, Jesus G. Berdeja, MD, and Ajai Chari, MD, discuss health disparities and equitable care strategies in multiple myeloma, including:
Treatment for underserved populations Navigating REMS for novel therapeutics Clinical trial design and enrolmentPresenters:
Jesus G. Berdeja, MD
Director of Myeloma Research
Greco-Hainsworth Centers for Research
Partner
Tennessee Oncology
Nashville, Tennessee
Ajai Chari, MD
Professor of Clinical Medicine
Director of Multiple Myeloma Program
UCSF Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco (UCSF) Medical Center
San Francisco, Ca...
Experts Discuss CELMoD Agents for Multiple Myeloma
In this podcast episode, Meletios-Athanasios (Thanos) C. Dimopoulos, MD, and María-Victoria Mateos, MD, PhD, as they discuss the use of CELMoD agents to manage multiple myeloma, including:
The recent FDA approval of iberdomide Mechanism of action and differentiation from IMiDs Current data and potential treatment settingsPresenters:
Meletios-Athanasios (Thanos) C. Dimopoulos, MD
Professor and Chairman
Plasma Cell Dyscrasias Unit
Section of Hematology and Medical Oncology
Department of Clinical Therapeutics
School of Medicine
National and Kapodistrian University of Athens
Alexandra Hospital
Athens, Greece
María-Victoria Mateos, MD...
Optimizing Oral Targeted Therapies for HR+/HER2- Breast Cancer
In this episode, Danielle Roman, PharmD, BCOP, and Jordan Hill, PharmD, BCOP, discuss optimal care for patients with HR-positive/HER2-negative breast cancer receiving newer oral targeted therapies. Their conversation addresses treatment selection across early-stage and metastatic disease, biomarker-informed decision-making, adverse event management, and practical strategies to help patients remain on therapy.
Key topics include:
Selecting and sequencing oral targeted therapies, including CDK4/6 inhibitors, PARP inhibitors, PI3K/AKT pathway inhibitors, and oral SERDs Identifying patients with high-risk early breast cancer and applying evidence from trials such as monarchE, NATALEE, and OlympiA Using biomarkers such as...TGCT Today: Understanding Diagnosis, Treatment, and Long-term Care
Tenosynovial giant cell tumor (TGCT) is a rare, locally aggressive disease that can cause chronic pain, joint dysfunction, reduced mobility, and significant impacts on quality of life, particularly in patients with diffuse disease. In this expert discussion, Dr William Tap and Dr Emanuela Palmerini explore the evolving management of TGCT, including the biologic role of the CSF1/CSF1R pathway, challenges in diagnosis and disease monitoring, and the importance of multidisciplinary, patient-centered care. They also discuss the growing role of CSF1R-targeted therapies, treatment selection, toxicity management, drug holidays, and practical approaches to optimizing long-term outcomes for patients living...
Optimizing Anti-CD38–Based Treatment for Smoldering and Newly Diagnosed Multiple Myeloma: Pharmacist Perspectives
In this podcast episode, James A. Davis, PharmD, BCOP, and Kelley L. Julian, PharmD, BCOP, discuss evidence-based strategies for managing smoldering and newly diagnosed multiple myeloma, including:
Risk stratification and treatment selection for smoldering multiple myeloma Anti-CD38–based regimens for transplant-eligible and transplant-ineligible patients Clinical evidence supporting triplet and quadruplet therapies MRD assessment and response-adapted treatment strategies Frailty, transplant eligibility, and individualized treatment selection Subcutaneous anti-CD38 administration and premedication requirements Pharmacist-led supportive care, toxicity management, dose modification, and patient counselingGet access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on...
New and Emerging Targeted Therapies for Patients With DLBCL
In this podcast episode, Gilles Salles, MD, PhD, and Pier Luigi Zinzani, MD, PhD, discuss the role of new and emerging targeted therapies in the management of patients with DLBCL, including:
Overview of Unmet Needs With Current Standard of Care in DLBCL Expanding Role of Novel Agents in DLBCL Access to Targeted Therapies and Clinical Trials in Non-Academic DLBCL Practice Key Ongoing Trials of new and novel agents in DLBCL Key Presentations/Results at EHA 2026 in DLBCLPresenters:
Gilles Salles, MD, PhD
Service Chief, Lymphoma Service
Steven Greenberg Chair
Memorial Sloan Kettering Canc...
Changing the Paradigm in HER2-Positive Early Breast Cancer
New data and broad indications for trastuzumab deruxtecan are changing the paradigm for HER2-positive early breast cancer. Listen to Shanu Modi, MD, and Sara A. Hurvitz, MD, FACP, discuss how they are incorporating these changes into clinical practice in the neoadjuvant, adjuvant, and possibly metastatic settings.
Presenters:
Sara A. Hurvitz, MD, FACP
Professor of Medicine
Smith Family Endowed Chair in Women’s Health
Senior Vice President, Clinical Research Division
Fred Hutch Cancer Center
Head, Division of Hematology/Oncology, Department of Medicine
University of Washington School of Medicine
Se...
Recent Advances, Future Directions, and Ideas on Integrating CELMoDs Into The Care Of Patients With Myeloma
Listen in to learn from Sagar Lonial, MD, and Mohamad Mohty MD, PhD, about the advantages and future implications of the next-generation protein degradation modulator based therapy and find out how to integrate their use into your practice.
Presenters:
Sagar Lonial, MD, FACP, FASCO
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia
Mohamad Mohty, MD, PhD
Sorbonne University
Paris, France
Get...
To Treat or Not to Treat: Assessing Risk and Treatment Options in High-Risk SMM
In this podcast episode, Natalie S. Callander, MD, and Tom Martin, MD, discuss the optimal approaches for the determination of whether a patient with high-risk SMM requires treatment or observation, including:
Contemporary Risk Stratification Interpreting Evidence for Early Intervention Treatment vs Observation: Patient Selection Treatment Selection and Sequencing Considerations Safety, Monitoring, and Supportive Care Implementation in Practice Shared Decision-making and Patient Communication Emerging Therapies and Clinical TrialsPresenters:
Natalie S. Callander, MD
Professor of Medicine
Director, Myeloma Clinical and
Cellular Therapy Program
University of Wisconsin Carbone
Cancer Center
Madison, Wisco...
Unmet Needs, Recent Advances, and Expert Insights on Integrating TROP-2 ADCs Into the Care of Patients With TNBC
Listen in to learn from Thomas Bachelot, MD, PhD, and Mafalda Oliveira, MD, PhD, about recent advances and the integration of anti-TROP2 antibody-drug conjugates (ADCs) into the management of patients with triple-negative breast cancer, including as first-line therapy for those who are not eligible for immunotherapy. Experts will cover:
The evolving role of TROP2-directed antibody-drug conjugates (ADCs), including sacituzumab govitecan and datopotamab deruxtecan, in addressing unmet needs in the frontline treatment of TNBC. Treatment sequencing, reimbursement barriers to recent approvals, and toxicity-informed treatment selection considerations. How to monitor and manage ocular and pulmonary toxicities and care-team readiness f...Optimizing Bispecific Antibody Safety and Care Coordination From the Pharmacy in RRMM
In this episode, Dr Sara Ann Scott and Dr Syeda Saba Kareem discuss toxicities and the safe management of bispecific antibodies used in the treatment of RRMM to improve outcomes for patients, including:
The incidence of cytokine release syndrome (CRS), along with the grading system, treatment strategies, and the role of tocilizumab Neurologic toxicities like the clinical manifestation of ICANS and the ICE scoring system used to help assign grading and appropriate treatment with dexamethasone, levetiracetam, and/or high-dose methylprednisolone Infection susceptibilities associated with BCMA-targeted bispecific antibodies and how this varies for GPRC5D-directed targets throughout therapy How...Targeting the Future of Pancreatic Cancer Care: RAS, Biomarkers, and Emerging Therapies
In this episode, Dr Paul E. Oberstein, Dr Andrew H. Ko, and Dr Efrat Dotan discuss recent advances in pancreatic cancer, including:
The evolving role of chemotherapy Utility of tumor treating fields for the treatment of locally advanced pancreatic adenocarcinoma Emerging RAS-targeted strategies and novel approaches for CLDN18.2- and MTAP-altered disease The potential impact of these developments on future treatment sequencing and supportive careGet access to all of our new podcasts by subscribing to the Decera Clinical Education Podcast on Apple Podcasts, YouTube Music, or Spotify.
Presenters:
Paul E. Oberstein, MD, M...
Beyond BCMA: How GPRC5D-Targeted Therapy Fits into Multiple Myeloma Care Today
Treatment options for patients with multiple myeloma are rapidly evolving. In this podcast episode, Jesus Berdeja, MD, and Amrita Krishnan, MD, FCAP, discuss GPRC5D-directed treatment options for patients with relapsed/refractory multiple myeloma, with a focus on talquetamab, a GPRC5D-directed bispecific antibody. Topic areas covered include:
Clinical trial updates and discussion of how findings may translate into clinical practice and FDA approvals Treatment sequencing and patient selection Step-up dosing and what to expect in terms of toxicity management when using a GPRC5D-targeted therapy with on-target, off-tumor effectsPresenters:
Jesus Berdeja, MD
...
What Oncology Pharmacists Need to Know About Targeting BCMA in Early Relapsed/Refractory Myeloma
In this podcast episode, Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP, FASHP, and Anthony Perissinotti, PharmD, BCOP, discuss the role, efficacy, and safety of agents targeting BCMA in the personalized care of patients with multiple myeloma after disease progression on 1 or 2 previous lines of therapy, including:
A Brief Overview of BCMA in Multiple Myeloma Advances in BCMA-Targeted Agents in Progressing Myeloma Selection of BCMA-Directed Therapies for Early Relapse MM Operational Challenges Faced by Oncology Pharmacists Regarding the Incorporation of BCMA-Targeted Agents in Practice Identifying and Managing Adverse Events Associated With BCMA-Directed AgentsPresenters:
Donald Moore, Pha...
Incorporating AKT1 and PIK3CA Pathway Testing and Targeted Therapies in the Management of Advanced Endocrine-Resistant Breast Cancer
Listen in to learn from Cristina Saura Manich, MD, PhD and Giampaolo Bianchini, MD about practical approaches to PI3K pathway testing, PI3K/AKT-targeted treatment options, and endocrine-based sequencing in metastatic breast cancer.
Presenters:
Cristina Saura Manich, MD, PhD
Head, Breast Cancer Unit
Medical Oncology Service
Vall d'Hebron University Hospital
Breast Cancer Program, Vall d'Hebron Institute of Oncology (VHIO)
Barcelona, Spain
Giampaolo Bianchini, MD
Associate Professor, Universita Vita-Salute San Raffaele
Head, Breast Cancer Group, Department of Medical Oncology
Head, Clinical Translational and Immunotherapy Research<...
Personalizing EGFR Mutation–Positive NSCLC Care: Strategies for the Advanced Practice Provider
Link to claim CME credit:
https://bit.ly/4uRr3ir
In this episode, Elizabeth Krueger, NP, and Sam Vafadar, DHSc, PA-C, discuss how they optimize first-line EGFR-targeted therapy for patients with EGFR-mutated NSCLC, including:
First-line treatment options available for EGFR-mutated NSCLC and the clinical trials that resulted in their approval Adverse event identification and management Generalized strategies to support patient adherence to TKIsGet access to all of our new podcasts by subscribing to the Decera Clinical Education Podcast on Apple Podcasts, YouTube Music, or Spotify
Presenters:
Elizabeth Krueger, NP
Advancing the Early Detection of Lung Cancer: Expanding Screening Access, Eligibility, and Awareness
In this episode, Dr Abbie Begnaud discusses the importance of lung cancer screening and evolving strategies to improve early detection among high-risk populations, including:
Low-dose CT screening, which reduces lung cancer mortality by detecting cancers at earlier, more treatable stages Updated screening guidelines that have expanded eligibility Key challenges that impact screening participation, including awareness, access, and broader risk assessmentGet access to all of our new podcasts by subscribing to the Decera Clinical Education [Oncology] Podcast on Apple Podcasts, YouTube Music, or Spotify.
Presenter:
Abbie Begnaud, MD, FCCP
Associate Professor of...
HNSCC: Current and Emerging Therapeutic Strategies
In this episode, Aarti Bhatia, MD, MPH, and Deborah J. Wong, MD, PhD, discuss the rapidly evolving treatment landscape for recurrent, metastatic, and locally advanced head and neck squamous cell carcinoma (HNSCC), including the growing role of immune checkpoint inhibitors, perioperative treatment strategies, EGFR-targeted bispecific antibodies, antibody–drug conjugates, HPV-targeted vaccines, and novel radiosensitizers. The discussion also explores emerging phase III clinical trials, treatment sequencing considerations, and future precision oncology approaches for HPV-positive and HPV-negative patients with head and neck cancer.
Presenters:
Aarti Bhatia, MD, MPH
Associate Professor of Medicine (Medical Oncology)
Clinical Rese...
Navigating Relapsed/Refractory Multiple Myeloma: Real-world Use of Bispecific Antibodies
In this episode, hear Doris K. Hansen, MD, discuss the management of relapsed/refractory multiple myeloma with bispecific antibodies including:
Practical differences among approved bispecific antibodies Toxicity profiles of approved bispecific antibodies When to refer patients for evaluation for immunotherapies Considerations for sequencing bispecific antibodies in the relapsed/refractory setting New findings with combination regimens with bispecific antibodiesProgram faculty:
Doris K. Hansen, MD
Assistant Member, Blood and Marrow Transplant and Cellular Immunotherapy
H. Lee Moffitt Cancer Center & Research Institute
Assistant Professor
University of South Florida Morsani College of Medicine
Tampa...
Oncologists “On Call”: Our Practical Experiences to Optimizing Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma
In this episode, Muhamed Baljevic, MD, FACP, and Johnathan Ticku, MD, discuss various strategies to optimize the use of bispecific antibodies in their practices for the treatment of R/R MM through patient monitoring, dosing in outpatient settings, and using tocilizumab and IVIG, among other management strategies.
Presenters:
Muhamed Baljevic, MD, FACP
Associate Professor of Medicine
Division of Hematology-Oncology
Department of Medicine
Director, Multiple Myeloma Program
Director, Vanderbilt Amyloidosis Multidisciplinary Program (VAMP)
Co-Chair, Scientific Review Committee, VICC
Disease Team Lead, Plasma Cell Dyscrasias and Lymphomas
Vanderbilt-Ingram Cancer Ce...
Thrombotic Events and ET/PV: What You Should Know
In this episode, hear Anthony Hunter, MD and Douglas Tremblay, MD discuss the various presentations of thrombotic events in patients with PV or ET including how thrombotic events may lead to diagnosis:
PV and ET increase the risk of both arterial and venous thrombotic events Unusual thrombotic events Thrombosis as initial presentation for MPN Case presentations Brief overview of thrombosis managementProgram faculty:
Anthony M. Hunter, MD
Associate Professor, Department of Hematology and Medical Oncology
Leader, Myeloproliferative Neoplasm Program
Medical Director, Rollins Immediate Care Center
Winship Cancer Institute of Emory University, Leu...
Global Experts Discuss Current and Emerging Treatments for ET and PV
In this podcast episode, Ciro Rinaldi MD, PhD, and Alessandro M. Vannucchi, MD, discuss contemporary management of essential thrombocythemia (ET) and polycythemia vera (PV), as well as novel investigational approaches, including the following:
Overview of current treatment paradigms for PV and ET Importance of shared decision-making and patient communication in determining treatment Current therapeutic areas of need in ET and PV Emerging investigational therapeuticsPresenters:
Ciro Rinaldi MD, PhD
Chief Medical Officer, United Lincolnshire Teaching Hospital
Honorary Professor of Haematology, University of Lincoln
Honorary Professor De Montfort University Dubai
Consultant Haematologist
Li...
Global Experts Discuss Diagnostic Considerations in ET and PV
In this podcast episode, Ciro Rinaldi, MD, PhD, and Alessandro M. Vannucchi, MD, as they discuss contemporary topics in diagnosing essential thrombocythemia (ET) and polycythemia vera (PV), including:
Overview of diagnostic criteria for PV and ET Importance of bone marrow biopsy Degree of suspicion of PV/ET in patients presenting with thrombotic events Pearls of wisdom in diagnosisPresenters:
Ciro Rinaldi, MD, PhD
Chief Medical Officer, United Lincolnshire Teaching Hospital
Honorary Professor of Haematology, University of Lincoln
Honorary Professor De Montfort University Dubai
Consultant Haematologist
Lincoln, United Kingdom
Ale...
Experts Discuss Novel Approaches to First-line Therapy for HER2-Positive Metastatic Breast Cancer
In this podcast episode, Erika Hamilton, MD, FASCO, and Ian Krop, MD, PhD, discuss recent developments in the field of first-line therapy and maintenance treatment for patients with HER2-positive metastatic breast cancer, including the following:
Trastuzumab deruxtecan plus pertuzumab as first-line therapy based on data from DESTINY-Breast09 Adding palbociclib to HP and ET as maintenance therapy for HR-positive/HER2-positive MBC, based on data from PATINA Adding tucatinib to HP as maintenance therapy for HER2-positive MBC, based on data from HER2CLIMB-05Presenters:
Erika Hamilton, MD, FASCO
Chief Development Officer, Late Phase
...
Patient Voices: Caring for the Whole Patient and Personalizing Treatment of Early Breast Cancer to Achieve Equitable Outcomes
A patient advocate/cancer survivor and a healthcare professional discuss key topics including early breast cancer diagnosis, role of self-agency in pursuing optimal cancer care, encouraging trial participation with patient testimonials, and other considerations for the patient care journey such as appropriate screening, follow-up encounters for questions, guideline-based treatments, and side effect management.
Participants
Kristen D. Whitaker, MD, MS
Breast Medical Oncologist
Medstar Georgetown Center Institute at Washington Hospital Center
Assistant Professor of Medicine
Georgetown University School of Medicine
Washington, DC
Asha Miller
Founder, Asha Miller Creative
Role of AKT and PI3K Inhibitors in Patients With HR-Positive Breast Cancers: Experts Share Their Thoughts on Current Practice and Future Opportunities
Podcast with global experts discussing the role of AKT and PI3K inhibitors in patients with resistance to endocrine therapy in the adjuvant or metastatic disease settings following current guidelines, indications, and best clinical practices.
Presenters:
Nadia Harbeck, MD
Breast Cancer Director
Department of OB&GYN and Comprehensive Cancer Center Munich
LMU University Hospital
Munich, Germany
Francois-Clement Bidard, MD, PhD
Breast Medical Oncology
Institut Curie & University of Versailles
Paris, France
Link to full program:
https://bit.ly/4cFd0Xj
Get access...
Patient-Centered Management of CDK4/6 Inhibitor Therapy: Adverse Event Mitigation, Adherence, and Persistence in HR+/HER2- Breast Cancer
In this episode, Danielle Roman, PharmD, BCOP, and Jordan Hill, PharmD, BCOP, discuss patient-centered management of CDK4/6 inhibitor therapy in HR-positive/HER2-negative breast cancer, with a focus on how oncology pharmacists and the multidisciplinary care team can support patients through treatment, including:
Practical strategies for monitoring and managing key adverse events associated with abemaciclib, ribociclib, and palbociclib, such as diarrhea, neutropenia, hepatotoxicity, and QT prolongation How dose interruptions and dose reductions can help improve tolerability while maintaining clinical benefit Real-world approaches to patient education, toxicity counseling, and communication that can improve adherence and persistence with oral CDK4/6...TROP2-Directed Antibody–Drug Conjugates in Non-Small-Cell Lung Cancer: Current Use in Clinical Practice and Future Directions
In this episode, Dr Matthew Gubens and Dr Helena Yu discuss the evolving role of TROP2-directed therapies in non-small-cell lung cancer, with a focus on how antibody–drug conjugates (ADCs) fit into current treatment strategies, including
The mechanism of action and clinical trial outcomes of TROP2-directed ADCs like datopotamab deruxtecan and sacituzumab tirumotecan Use of these therapies in EGFR-mutant disease and how they fit into a changing treatment landscape Practical advice on associated adverse events and additional considerations, A look at future directions on the horizon, such as first-line studies and predictive biomarkersGet access to...
Emerging Therapies for Patients With HER2+ Gastroesophageal Adenocarcinoma and Biliary Tract Cancer
In this podcast episode, Amit Mahipal, MD, MPH, and Shubham Pant, MD, discuss new and emerging therapies for the individualized care of patients with HER2-positive gastroesophageal adenocarcinoma and biliary tract cancer, including:
A brief overview of BTC and GEA Notable findings from a recent survey of healthcare professionals on BTC and GEA Case studies on recommended management of patients with BTC or GEA Emerging datasets of HER2-directed therapies in BTC and GEA affecting clinical practice Challenges faced by healthcare professionals in the management of patients with BTC and/or GEA Key ongoing trials of HER2-directed th...Experts Discuss ADCs for HER2-Negative/Ultralow/Low MBC
In this podcast episode, Aditya Bardia, MD, MPH, FASCO, and Ruta Rao, MD, discuss ADCs for HER2-negative/ultralow/low metastatic breast cancer, including:
Classifying HER2 expression in MBC today (HER2 negative/ultralow/low/positive) and why this is important ADCs for HER2-negative/ultralow/low MBC Patient communication: best practices in discussing treatment goals and potential AEsPresenters:
Aditya Bardia, MD, MPH, FASCO
Professor of Medicine
Geffen School of Medicine
University of California
Los Angeles, California
Ruta Rao, MD
Medical Director, Rush University Cancer Center
Professor of M...
Advanced Practice Professionals on Biomarker Testing in Patients With Solid Tumors: Colorectal Cancer
Advanced practice providers discuss biomarker testing in patients with colorectal cancer. Listen in to learn from Ann Marie Siney, RN, MSN, ANP-BC, and Kathleen Boyle, DScPAS, PA-C, about familial cancer syndromes associated with colorectal cancer and key biomarker testing often used in patients with colorectal cancer, including their thoughts on overcoming key barriers to testing, education of patients and caregivers, and improving equity in the application of biomarker for all patients.
Presenters:
Ann Marie Siney, RN, MSN, ANP-BC
Division of Hematology/Oncology
UCLA Health
Santa Monica, California
Kathleen Boyle, DScPAS...
